An international study to Compare the Efficacy and Safety of Romosozumab With Placebo in Men With Osteoporosis

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-005551-32

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the effect of treatment with romosozumab for 12 months compared with placebo on percent changes in bone mineral density (BMD) at the lumbar spine as assessed by dual energy x ray absorptiometry (DXA) in men with osteoporosis.


Critère d'inclusion

  • Male Osteoporosis